Biohaven LTD Form 4 insider transactions

John W. Childs files an amendment to a previous Form 4 to correct the nature of indirect ownership of Biohaven Ltd. shares acquired through a public offering.

Biohaven's Chief Scientific Officer, Bruce Car, reported the acquisition and disposal of company stock and stock options on January 5, 2025.

Biohaven's SVP of Clinical Operations, Kimberly Gentile, reported the acquisition of shares and stock options, as well as the disposal of shares to cover tax obligations.

Biohaven's VP, Chief Accounting Officer, George Clark, reported the acquisition of shares, stock options, and restricted share units, along with the withholding of shares for tax purposes.

Biohaven's Chief Financial Officer, Matthew Buten, reported the acquisition of shares and stock options, as well as the withholding of shares for tax purposes, on January 5, 2025.

Biohaven CEO Vlad Coric reported the acquisition of stock options and restricted share units, along with the withholding of shares for tax purposes.

Biohaven director John W. Childs purchased 29,000 common shares at a weighted average price of $35.9446 on December 30, 2024.

Director John W. Childs acquired 21,052 common shares of Biohaven Ltd. through an underwritten public offering on October 2, 2024.

Biohaven CEO Vlad Coric reports the acquisition of 21,052 common shares at $47.50 each through an underwritten public offering.

Director Gregory Bailey increased his stake in Biohaven Ltd. by purchasing 5,000 common shares at an average price of $44.1932 on September 24, 2024.

Director John W. Childs recently purchased 28,400 shares of Biohaven Ltd. at an average price of $35.6684 per share, increasing his indirect holdings.

Bruce Car, Chief Scientific Officer of Biohaven Ltd., reports the acquisition of 30,000 common shares at a price of $33.583 per share on June 17, 2024.

Director John W. Childs purchased 28,000 shares of Biohaven Ltd. at an average price of $35.58 on May 30, 2024.

Biohaven Ltd. Director Gregory Bailey recently purchased 15,000 common shares of the company at a weighted average price of $34.1918, increasing his total holdings to 1,615,071 shares.

John W. Childs, a director at Biohaven Ltd., recently purchased 28,500 common shares of the company at an average price of $35.1744.

Director Kishan Mehta acquired 16,592 stock options in Biohaven Ltd. on April 30, 2024.

Director Michael Heffernan acquired stock options for 16,592 common shares of Biohaven Ltd. on April 30, 2024.

Director Julia P. Gregory acquired 16,592 stock options in Biohaven Ltd. on April 30, 2024.

Director Robert J. Hugin acquired 16,592 stock options in Biohaven Ltd. on April 30, 2024.

Director Irina Antonijevic acquired 16,592 stock options in Biohaven Ltd. on April 30, 2024.

Director John W. Childs acquired 16,592 stock options in Biohaven Ltd. on April 30, 2024.

Director Gregory Bailey acquired 16,592 stock options in Biohaven Ltd. on April 30, 2024.

Gregory Bailey, a director at Biohaven Ltd., purchased 25,503 common shares at a weighted average price of $39.1785 on April 24, 2024.

Gregory Bailey, a director of Biohaven Ltd., purchased 48,780 common shares at $41 per share in an underwritten public offering, increasing his total holdings to 1,574,568 shares.

Director John W. Childs reports acquiring additional Biohaven shares through various charitable remainder trusts and a revocable trust.

Biohaven CEO Vlad Coric reports the acquisition of 121,951 common shares through a public offering at $41 per share, along with holdings in 401(k) and family trusts.

Director John W. Childs receives additional Biohaven shares to correct a calculation error related to a previous merger transaction.

Biohaven CEO Vlad Coric received an additional 694 common shares on April 5, 2024, to correct a calculation error related to a merger transaction completed on January 8, 2024.

Director John W. Childs reports acquisition of Biohaven Ltd. shares following a merger agreement.

Biohaven CEO Vlad Coric reports acquisition of common shares on March 8, 2024, following a merger agreement.